Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15886168 | 0.77 | ALDH1A1 (0.36) | ALDH1A1KDM4EPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL17352347 | 0.76 | CASR (0.36) | CHRM3 | |
| SCHEMBL15875002 | 0.76 | CHRM2 (0.37) | ALDH1A1KDM4EPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL28397568 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP3A4MAPK1ESR1 | |
| SCHEMBL29407021 | 0.69 | KCNN4 (0.34) | ALDH1A1KDM4EKMT2AMEN1CYP3A4 | |
| SCHEMBL29213035 | 0.68 | NR1H2 (0.35) | ALDH1A1KDM4EPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL3351394 | 0.67 | MAPK1 (0.38) | ALDH1A1KMT2ACYP3A4MAPK1ESR1 | |
| SCHEMBL12477372 | 0.66 | MAPK1 (0.33) | ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL31252158 | 0.66 | KDM4E (0.47) | ALDH1A1KDM4EPABPC1APOBEC3AAPOBEC3G | |
| SCHEMBL20636562 | 0.66 | ALDH1A1 (0.37) | ALDH1A1KDM4EPABPC1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10159966-B2 | Catalyst complexes with carbene ligand and method for making same and use in metathesis reaction | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2018-12-25 | — | — | US | disclosed |
| US-20150367338-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2015-12-24 | — | — | US | disclosed |
| US-20150367338-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2015-12-24 | — | — | US | disclosed |
| US-20150367338-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159966-B2 | Catalyst complexes with carbene ligand and method for making same and use in metathesis reaction | MSMO1, ALOX12, SQLE | ALDH1A1 1136/4885KDM4E 2851/4885PABPC1 4544/4885 |
| US-20150367338-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | MSMO1, ALOX12, SQLE | ALDH1A1 1136/4885KDM4E 2851/4885PABPC1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.